Phase III study of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone in nonmetastatic high-risk prostate cancer (PC) patients (pts): Final results on PSA progression-free survival

Stéphane Oudard, Stéphane Culine, Philippe Beuzeboc et al.|Journal of Clinical Oncology|2011

Cited by 3